Clay Siegall Tackles Cancer Head On

According to a statistic that was recently released by the National Cancer Institute, over the course of a lifetime, about forty percent of people today will be diagnosed with some form of cancer. Dr. Clay Siegall, co-founder, and CEO of Seattle Genetics took his company to new heights in recent years by championing research concerning the development of therapeutic drugs to be used in the treatment of diseases with high rates of mortality. The general focus of Dr. Siegall and the staff at Seattle Genetics has been geared at using revolutionary scientific techniques to attack these existing diseases. In the oncology biotechnology area, Dr. Siegall is considered a leader and an innovator, and he has recently been delving into the virtually untapped market of antibody-drug conjugates, which in his estimation, will do wonders for those suffering from cancer. Antibody drug conjugates can be used to target specific conditions much more efficiently than many drugs that are currently on the market; this has made them frontrunners in the war against cancer and other serious diseases. Hodgkin’s lymphoma, an extremely common form of cancer that attacks the immune system and white blood cells, affects over 70,000 people each year. Antibody drug conjugates have been seen as major prospects for the treatment of Hodgkin’s lymphoma, as well as other common types of lymphoma. Recently Clay Siegall and his team at Seattle Genetics entered into a partnership with Takeda Pharmaceutical Company Limited in an effort to increase commercial distribution. Together they have created ADCetris, which is currently distributed to over 60 countries around the world. While ADCetris has already been effective at treating lymphoma, Dr. Siegall, along with Seattle Pharmaceuticals and Takeda Pharmaceutical Company Limited, have been working on making the drug more effective in treating acute myeloid leukemia.

Dr. Clay Siegall, co-founder and Chief Executive Officer of Seattle Genetics, has been heavily involved in heading cancer treatment research and therapeutic drug development. Prior to founding Seattle Genetics in 1997, Dr. Siegall worked for Bristol-Meyers Squibb Pharmaceutical Research Institute beginning in 1991. He has won several awards for the advancements made in his field, including the Pierce Award.